(UroToday.com) Globally, prostate cancer is a disease of the aging male, with an average age of diagnosis of 65 years, which increases in prevalence with exposure to screening and diagnostic testing. In high-income countries, prostate cancer is already prevalent and exerting a significant societal burden, with morbidity secondary to disease and treatment. As life expectancy and access to testing increases in low-income countries, so will prevalence of age-related diseases. The Global Burden of Disease dataset is an aggregation of worldwide cancer registries and health data systems that reports a global and regional assessment of disease impact. At the 2020 American Urological Association Virtual Annual Meeting, Bryn Launer and colleagues assessed the global interaction of economic status with prostate cancer burden.